Le Registre des lobbyistes
Version 4 de 8 (1998-01-19 à 1998-08-11) a été soumis avant l'entrée en vigueur de la Loi sur le lobbying, le 2 juillet 2008. En raison d'exigences de renseignements différents à ce moment-là, l'enregistrement est présenté sous le format suivant.
| Organisation : |
CANADIAN SOCIETY OF HOSPITAL PHARMACISTS (CSHP)
350 - 1145 HUNT CLUB ROAD OTTAWA, ON K1V 0Y3 Canada |
| Numéro de téléphone : | 613-736-9733 |
| Numéro de fax : | 613-736-5660 |
| Nom et poste de l'agent responsable pendant la période de cet enregistrement : | WILLIAM J LESLIE, EXECUTIVE DIRECTOR |
| Description des activités de l'organisation : | THE CANADIAN SOCIETY OF HOSPITAL PHARMACISTS (CSHP) IS THE NATIONAL VOLUNTARY ORGANIZATION OF PHARMACISTS WHO SHARE AN INTEREST IN PHARMACY PRACTICE IN HOSPITALS AND RELATED HEALTH CARE SETTINGS.CSHP'S VISION IS: COMMITTED CAREGIVERS.... CHALLENGING EACH OTHER THROUGH SHARING & EDUCATION , LEADING PHARMACY THROUGH STANDARDS & INNOVATION. THE RELATED VISION OBJECTIVES ARE:1- ENCOURAGE MEMBERS TO DEVELOP & SHARE INNOVATIVE DIRECT PATIENT CARE PRACTIVE MODELS & EXPERIENCE2- PROMOTE THE DIRECT PATIENT CARE ROLE OF THE PHARMACIST TO: MEMBERS, PATIENTS, EDUCATORS, STUDENTS, GOV'T, HEALTH CARE PROVIDERS & ORGANIZATIONS3- PROVIDE ACCESSIBLE EDUCATION TO ASSIST MEMBERS IN ACHIEVING A DIRECT PATIENT CARE ROLE |
| Membres ou types de membres de l'organisation. : | 1- ACTIVE MEMBERS ARE PHARMACISTS LICENSED OR REGISTERED WITH A PHARMACY REGULATORY BODY IN CANADA OR PERSONS WITH A PROFESSIONAL DEGREE IN PHARMACY2- HONORARY MEMBERS - ELECTED BY A 2/3 VOTE OF THE COUNCIL OF THE SOCIETY3- STUDENT MEMBERS ARE PERSONS ENROLLED IN A BACCALAUREATE DEGREE PROGRAM IN PHARMACY4- SUPPORTING MEMBERS ARE PERSONS NOT ELIGIBLE FOR OTHER MEMBERSHIP CATEGORIES5- CORPORATE MEMBERS ARE CORPORATIONS WHO SUPPORT THE OBJECTIVES OF AND PAY FEES TO THE SOCIETY |
| L'organisation a-t-elle été financée en tout ou en partie par une institution gouvernementale domestique ou étrangère au cours du dernier exercice financier complet? | Non |
| Nom : | WILLIAM LESLIE |
| Titre du poste : | EXECUTIVE DIRECTOR |
| Charges publiques occupées : | S/O. La divulgation de cette information n'était pas une exigence avant le 20 juin 2005. |
| Institutions fédérales qui ont été ou seront consultées au cours de l'engagement. : | Conseil d'examen du prix des médicaments brevetés (CEPMB), DRUGS DIRECTORATE, HEALTH PROTECTION BRANCH, Environnement Canada, Industrie Canada, Santé Canada (SC) |
|
Techniques de communication déjà utilisées ou qui seront utilisées au cours de l'engagement :
|
Appels téléphoniques, Communications informelles, Communications écrites, en format papier ou électronique, Réunions |
| Objet : Sujets de préoccupation : | Santé |
| Objets poursuivis : Renseignements rétrospectifs : | ONGOING JOINT INITIATIVE WITH TPD (THERAPEUTIC PRODUCTS DIR.) REGARDING ESTABLISHMENT LICENSES & HOSPITAL COMPOUNDING PRACTICES; DISCUSSIONS WITH TPD ON USP MEDICATION INCIDENT REPORTING AND POSSIBLE CANADIAN APPLICATONS; RESPONSES TO REQUESTS FOR INPUT: RX TO OTC SWITCH FOR NIZATIDINE 75 MGS., RX TO OTC SWITCH FOR NICOTINE PATCHES; SPECIAL ACCESS PROGRAMME; DRAFT GUIDELINES FOR INCLUSION OF PAEDIATRIC PATIENTS IN CLINICAL TRIALS; POLICY ON SUBMISSION REQUIREMENTS FOR TOPICAL NSAID'S; RX TO OTC SWITCH FOR SODIUM CROMOGLYCATE NASAL SOLUTION 2%; ESTABLISHMENT LICENSE FEE REGULATIONS; POLICY ON DEREGULATION OF PROHIBITED SUBSTANCES; "LOOK ALIKE SOUND ALIKE" ( LASA) DRUG NAMES; NARCOTIC & CONTROLLED DRUG INSPECTIONS; CLARIFY ISSUE OF DRUG RESEARCH LAB CLOSURES; ELECTRONIC HOSPITAL CHART & ELECTRONIC SIGNATURE FOR NARCOTIC & CONTROLLED DRUG ORDERS; BLOOD SYSTEM SYMPOSIUM; TPD COST RECOVERY III CONSULTATIONS; TPD PRODUCT LICENSING FRAMEWORK; ELIMINATION OF CFC'S FROM METERED DOSE INHALERS; F/P/T REPORT ON PHARMACEUTICAL COSTS & UTILIZATION; NATIONAL PHARMACARE PROGRAM CONSULTATIONS WORIKRESM 4 MG.; REGULATIONS FOR WOMEN IN CLINICAL TRIALS; REGULATIONS FOR HUMAN NEW DRUG SUBMISSION [ BIOTECHNOLOGY]; REGULATIONS FOR PRODUCT MONOGRAPHS; REGULATIONS FOR ESTABLISHMENT LICENSES; COMPARATIVE DRUG ADVERTISING CLAIMS; BIOEQUIVALENCE REQUIREMENTS; REGS FOR NEW CONTROLLED SUBSTANCES ACT; GUIDELINES FOR RADIOPHARMACEUTICAL Q.A.; REGS FOR COSMETIC PRODUCTS - LABEL & CLAIM ISSUES; SPECIAL ACCESS PROGRAM; REGS FOR SUPPLEMENTAL NEW DRUG SUBMISSIONS; RX TO OTC SWITCH FOR RANITIDINE 75 MG.; STANDARDS FOR COMPARATIVE BIOAVAILABILITY STUDIES; NOTICE OF COMPLIANCE WITH CONDITIONS POLICY; PRINCIPLES FOR DIRECT TO CONSUMER ADS; NUMEROUS MEETINGS RE: ESTABLISHMENT LICENSES & HOSPITAL COMPOUNDING PRACTICES (GMP & HOSPITAL PHARMACY); C-91 [ DRUG PATENTS]; PARTIPATION IN HEALTH CANADA'S WORKSHOPS ON ANTIBIOTIC RESISTANCE & ON CFC PROPELLANTS. |
| Objets poursuivis : Renseignements prospectifs : | CONTINUE TO WORK WITH TPD (THERAPEUTIC PRODUCTS DIR) ON POLICY AND HOSPITAL BASED DRUG COMPOUNDING; RESPOND TO RELEVANT HEALTH RELATED ITEMS PUBLISHED IN CANADA GAZETTE; RESPOND TO TPD REQUESTS FOR INPUT & PARTICIPATION IN WORKSHOPS; PARTICIPATE IN DISCUSSIONS ON NATIONAL PHARMACARE PROGRAM. |